Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018'; Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 39 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.
Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes.
Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha.
The report 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018' outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 14 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Oropharyngeal Cancer, Hepatocellular Carcinoma, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Carcinoma, Penile Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Vaginal Cancer and Vulvar Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018'; Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 39 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.
Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes.
Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha.
The report 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018' outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 14 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Oropharyngeal Cancer, Hepatocellular Carcinoma, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Carcinoma, Penile Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Vaginal Cancer and Vulvar Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)
- The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Protein E7 (E7) - Overview
Human Papillomavirus Protein E7 (E7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development
Abion Inc
Advaxis Inc
Bioleaders Corp
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Formune SL
Genexine Inc
Hookipa Biotech AG
iBio Inc
Immunovaccine Inc
Inovio Pharmaceuticals Inc
MedImmune LLC
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
VLPbio
Human Papillomavirus Protein E7 (E7) - Drug Profiles
ABN-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axalimogene filolisbac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axalimogene filolisbac second generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSILSB-710c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVAC-C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CerviVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPXE-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDA-HPVE7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLBL-101c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [Serotype 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-0457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CIN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tricurin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTFC-E7SH - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Protein E7 (E7) - Dormant Products
Human Papillomavirus Protein E7 (E7) - Discontinued Products
Human Papillomavirus Protein E7 (E7) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer
Jan 29, 2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase
Dec 05, 2017: Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice President and General Counsel
Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112
Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference
Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017
Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
May 18, 2017: Advaxis to Host Investor & Analyst Day on June
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Human Papillomavirus Protein E7 (E7) - Overview
Human Papillomavirus Protein E7 (E7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development
Abion Inc
Advaxis Inc
Bioleaders Corp
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Formune SL
Genexine Inc
Hookipa Biotech AG
iBio Inc
Immunovaccine Inc
Inovio Pharmaceuticals Inc
MedImmune LLC
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
VLPbio
Human Papillomavirus Protein E7 (E7) - Drug Profiles
ABN-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axalimogene filolisbac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axalimogene filolisbac second generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSILSB-710c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVAC-C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CerviVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPXE-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDA-HPVE7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLBL-101c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [Serotype 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-0457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CIN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tricurin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTFC-E7SH - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Protein E7 (E7) - Dormant Products
Human Papillomavirus Protein E7 (E7) - Discontinued Products
Human Papillomavirus Protein E7 (E7) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer
Jan 29, 2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase
Dec 05, 2017: Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice President and General Counsel
Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112
Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference
Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017
Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
May 18, 2017: Advaxis to Host Investor & Analyst Day on June
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abion Inc, H1 2018
Pipeline by Advaxis Inc, H1 2018
Pipeline by Bioleaders Corp, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Cancer Research Technology Ltd, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by Formune SL, H1 2018
Pipeline by Genexine Inc, H1 2018
Pipeline by Hookipa Biotech AG, H1 2018
Pipeline by iBio Inc, H1 2018
Pipeline by Immunovaccine Inc, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Selecta Biosciences Inc, H1 2018
Pipeline by Touchlight Genetics Ltd, H1 2018
Pipeline by Transgene SA, H1 2018
Pipeline by VLPbio, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abion Inc, H1 2018
Pipeline by Advaxis Inc, H1 2018
Pipeline by Bioleaders Corp, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Cancer Research Technology Ltd, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by Formune SL, H1 2018
Pipeline by Genexine Inc, H1 2018
Pipeline by Hookipa Biotech AG, H1 2018
Pipeline by iBio Inc, H1 2018
Pipeline by Immunovaccine Inc, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Selecta Biosciences Inc, H1 2018
Pipeline by Touchlight Genetics Ltd, H1 2018
Pipeline by Transgene SA, H1 2018
Pipeline by VLPbio, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
Abion Inc
Advaxis Inc
Bioleaders Corp
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Formune SL
Genexine Inc
Hookipa Biotech AG
iBio Inc
Immunovaccine Inc
Inovio Pharmaceuticals Inc
MedImmune LLC
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
VLPbio
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
Abion Inc
Advaxis Inc
Bioleaders Corp
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Formune SL
Genexine Inc
Hookipa Biotech AG
iBio Inc
Immunovaccine Inc
Inovio Pharmaceuticals Inc
MedImmune LLC
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
VLPbio
